Pune, India -- (SBWIRE) -- 02/23/2018 -- The report "In Vitro Diagnostics (IVD) Quality Control Market by Products & Services (Data Management Solutions, Quality Control Products and Quality Assurance Services), Application (Immunochemistry, Microbiology, Clinical Chemistry, Molecular Diagnostics, Clinical Chemistry, Hematology and Other Applications), Manufacturer Type (OEMS and Third-Party Control Manufacturers), End User (Clinical Laboratories, Hospitals, Research and Academic Institutes and Other End Users) - Global Industry Analysis, Trends analysis and Forecast up to 2023 studies the world as well as regional markets including North America, Europe, Asia Pacific and RoW (Including Latin America, Middle East and Africa)", The In Vitro Diagnostics (IVD) Quality Control market is expected to reach USD 1.1 Billion by 2023 expanding at a CAGR of 3.5%. Factors driving the growth of this market include rising demand for External Quality Assessment (EQA) support, number of accredited clinical laboratories are increasing, acceptance of Third-Party Quality controls is increased, and favorable Government regulation.

Get Free Sample Pages of this Report: https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/714

Quality Control Product is estimated to Account for the Largest Share of the Market in 2017

By products and services, the In Vitro Diagnostics (IVD) Quality Control market is classified into data management solutions, quality control products and quality assurance services. The quality control product segment is expected to lead the global In Vitro Diagnostics (IVD) Quality Control in 2017. Factors driving the growth of this segment include increasing adoption of quality control products to accredit reliability, accuracy and precision of IVD test procedures as well as continuous advancements in the in vitro diagnostic technologies.

Molecular Diagnostic is estimated to Command the Largest Share of the Market during the Forecast Period

Based on application, the In Vitro Diagnostics (IVD) Quality Control market is categorized into immunochemistry, microbiology, clinical chemistry, molecular diagnostics, clinical chemistry, hematology and other applications. The molecular diagnostic segment is estimated to account for the largest share of the global In Vitro Diagnostics (IVD) Quality Control market during the forecast period. Increasing adoption of molecular diagnostics owing to its high specificity and accuracy as well as rising number of molecular diagnostics test performed are the key factors driving the growth of this application segment.

Get 15% Discount on this Report: https://www.infiniumglobalresearch.com/Reports/requestdiscount/714

North America is estimated to Command the Largest Share of the Market

Based on region, the In Vitro Diagnostics (IVD) Quality Control market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the In Vitro Diagnostics (IVD) Quality Control market in 2017. This is attributed to factors such as stringent guidelines for using IVD controls, rising approvals for number of IVD products as well as presence of large number of clinical laboratories in the region.

Companies Profiled Covered in this Report:

The report profiles some of the key companies in the In Vitro Diagnostics (IVD) Quality Control market including Roche Diagnostics, Thermo Fisher Scientific Inc., Helena Laboratories, Randox Laboratories Ltd, Seracare Life Sciences, Inc., Sero as, Technopath Clinical Diagnostics., Ortho Clinical Diagnostics, Inc., Abbott Laboratories Inc., Bio-Rad Laboratories, Inc.

Browse Complete TOC of this Report: https://www.infiniumglobalresearch.com/healthcare_medical_devices/glzobal_in_vitro_diagnostics_quality_control_market